Viatris CapEx decreased by 79.7% to $39.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.3%, from $42.60M to $39.90M. Over 4 years (FY 2021 to FY 2025), CapEx shows a downward trend with a -4.6% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $89.30M | $121.00M | $197.40M | $64.50M | $83.90M | $103.90M | $153.70M | $47.80M | $67.80M | $95.90M | $165.50M | $49.80M | $58.80M | $77.00M | $140.40M | $42.60M | $52.90M | $86.80M | $196.50M | $39.90M |
| QoQ Change | — | +35.5% | +63.1% | -67.3% | +30.1% | +23.8% | +47.9% | -68.9% | +41.8% | +41.4% | +72.6% | -69.9% | +18.1% | +31.0% | +82.3% | -69.7% | +24.2% | +64.1% | +126.4% | -79.7% |
| YoY Change | — | — | — | — | -6.0% | -14.1% | -22.1% | -25.9% | -19.2% | -7.7% | +7.7% | +4.2% | -13.3% | -19.7% | -15.2% | -14.5% | -10.0% | +12.7% | +40.0% | -6.3% |